Anmelden Kostenlos registrieren

Beam Therapeutics 1-Jahres-Ziel

Was ist das 1-Jahres-Ziel von Beam Therapeutics?

1-Jahres-Ziel von Beam Therapeutics Inc. ist $89 +270.85%

Was ist die Definition von 1-Jahres-Ziel?

1-Jahres-Ziel ist ein prognostizierter Aktienkurs pro Jahr.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

1-Jahres-Ziel von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Beam Therapeutics

Was macht Beam Therapeutics?

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Unternehmen mit 1-jahres-ziel ähnlich Beam Therapeutics